We invite you to learn more about our clinical-stage targeted radiotherapy programs.
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing targeted radiotherapies to meaningfully improve survival for patients with relapsed or refractory cancer who have failed existing therapies. We deploy our industry leading technology platform and IP to develop ARCs, or Antibody Radiation Conjugates, and next-generation radiotherapies. Our lead candidate, Iomab-B (131I-apamistamab) has been studied in over 400 patients, including the positive pivotal Phase 3 SIERRA trial for bone marrow transplant conditioning, meeting the primary endpoint with high statistical significance. We are also working on a next-generation conditioning program, Iomab-ACT, for rapidly growing cell and gene therapies. Our industry-leading clinical program with Actimab-A, a CD33 targeting ARC using the potent alpha emitting isotope Ac-225, has been studied in approximately 150 patients. We have a CRADA with the National Cancer Institute (NCI) to develop Actimab-A with chemotherapy, immunotherapy, targeted agents and other novel combinations. In addition, we have ongoing solid tumor programs at the pre-clinical stage with investigational new drug (IND) enabling studies underway.
Brands: Iomab-B (Phase 3 Complete) for relapsed/refractory AML and BMT
Iomab-ACT (Phase 1/2) for CAR-T, Cell & Gene Therapy
Actimab-A + CLAG-M (Phase 1 Complete) for AML
Actimab-A + Venetoclax (Phase 1/2) for AML